Post-Marketing Data Will Drive Coverage Decisions Under Medicare, CMS Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
"The nexus between payment and reimbursement and approval is going to be awfully tight now that we're in a prescription drug benefit," CMS Senior Policy Advisor Trysla says.
You may also be interested in...
McClellan To Head Medicare Rx Law Implementation: Will Greater FDA/CMS Cooperation Ensue?
President Bush nominates FDA Commissioner McClellan to head Centers for Medicare & Medicaid Services Feb. 20. McClellan's closest advisors will remain at FDA, suggesting era of greater cooperation between the two agencies could result.
AHRQ Comparative Effectiveness Research Supported By GOP; Too Late For Budget Request
AHRQ budget request includes just $12 mil. for comparative effectiveness research. Majority Leader Frist, White House say they plan to work on $50 mil. appropriated in Medicare law.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.